Daiwa Securities Group’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-909
| Closed | -$2K | – | 1367 |
|
|
2025
Q4 | $2K | Hold |
909
| – | – | ﹤0.01% | 1317 |
|
|
2025
Q3 | $1K | Hold |
909
| – | – | ﹤0.01% | 1316 |
|
|
2025
Q2 | $1K | Hold |
909
| – | – | ﹤0.01% | 1274 |
|
|
2025
Q1 | $1K | Hold |
909
| – | – | ﹤0.01% | 1241 |
|
|
2024
Q4 | $2K | Hold |
909
| – | – | ﹤0.01% | 1225 |
|
|
2024
Q3 | $2K | Sell |
909
-234,399
| -100% | -$385K | ﹤0.01% | 1224 |
|
|
2024
Q2 | $322K | Buy |
235,308
+9,516
| +4% | +$19.2K | ﹤0.01% | 905 |
|
|
2024
Q1 | $846K | Buy |
225,792
+224,883
| +24,740% | +$1.32M | ﹤0.01% | 743 |
|
|
2023
Q4 | $9K | Hold |
909
| – | – | ﹤0.01% | 1174 |
|
|
2023
Q3 | $8K | Hold |
909
| – | – | ﹤0.01% | 1136 |
|
|
2023
Q2 | $12K | Hold |
909
| – | – | ﹤0.01% | 1132 |
|
|
2023
Q1 | $11K | Hold |
909
| – | – | ﹤0.01% | 1106 |
|
|
2022
Q4 | $7K | Buy |
909
+227
| +33% | +$1.96K | ﹤0.01% | 1132 |
|
|
2022
Q3 | $4K | Hold |
682
| – | – | ﹤0.01% | 1178 |
|
|
2022
Q2 | $3K | Hold |
682
| – | – | ﹤0.01% | 1206 |
|
|
2022
Q1 | $6K | Hold |
682
| – | – | ﹤0.01% | 1162 |
|
|
2021
Q4 | $14K | Hold |
682
| – | – | ﹤0.01% | 1135 |
|
|
2021
Q3 | $17K | Buy |
682
+300
| +79% | +$8.89K | ﹤0.01% | 1113 |
|
|
2021
Q2 | $13K | Hold |
382
| – | – | ﹤0.01% | 1034 |
|
|
2021
Q1 | $13K | Buy |
382
+30
| +9% | +$1.05K | ﹤0.01% | 1032 |
|
|
2020
Q4 | $9K | Sell |
352
-512
| -59% | -$8.7K | ﹤0.01% | 1023 |
|
|
2020
Q3 | $9K | Hold |
864
| – | – | ﹤0.01% | 1048 |
|
|
2020
Q2 | $3K | Hold |
864
| – | – | ﹤0.01% | 1142 |
|
|
2020
Q1 | $3K | Hold |
864
| – | – | ﹤0.01% | 1141 |
|
|
2019
Q4 | $4K | Sell |
864
-96
| -10% | -$488 | ﹤0.01% | 1129 |
|
|
2019
Q3 | $5K | Hold |
960
| – | – | ﹤0.01% | 1075 |
|
|
2019
Q2 | $6K | Hold |
960
| – | – | ﹤0.01% | 1083 |
|
|
2019
Q1 | $7K | Buy |
960
+318
| +50% | +$2.3K | ﹤0.01% | 1058 |
|
|
2018
Q4 | $5K | Hold |
642
| – | – | ﹤0.01% | 1056 |
|
|
2018
Q3 | $3K | Hold |
642
| – | – | ﹤0.01% | 1110 |
|
|
2018
Q2 | $2K | Hold |
642
| – | – | ﹤0.01% | 1144 |
|
|
2018
Q1 | $1K | Buy |
+642
| New | +$1.67K | ﹤0.01% | 1152 |
|
Other funds holding PACB
AIM
VCM
NAMA
Daiwa Securities Group's PACB Position: Q1 2026 in Review
Daiwa Securities Group sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 909 shares — an estimated $2K sold.
Daiwa Securities Group first reported a position in PACB in Q1 2018 and held it in 32 quarters. The position peaked at $846K in Q1 2024. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.
- Daiwa Securities Group reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
- Daiwa Securities Group sold 909 Pacific Biosciences shares in Q1 2026, an estimated $2K.
- Daiwa Securities Group first reported a position in Pacific Biosciences in Q1 2018 and held it in 32 quarters.
- Daiwa Securities Group's Pacific Biosciences position peaked at $846K in Q1 2024.
- 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.
Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.